With over 25 years of comprehensive clinical development expertise spanning biotech companies, CROs, and academic research sites, I have contributed to advance novel therapies across diverse therapeutic areas such as oncology, immunology, virology, etc. in global Phase 1-4 programs, driving regulatory submissions, and achieving approvals for significant HIV therapies at Gilead Sciences. I’ve held various Clinical Operations leadership roles at Amgen, Gilead, and currently at Profound Bio as Executive Director heading Clinical Operations department.
